Similarly, small benzimidazole-based molecules were studied as both BChE inhibitors and as human cannabinoid receptor agonists, highlighting the possible future development of a dual-acting therapeutic to treat AD [206]. This evidence concerns the gene BCHE and Alzheimer disease.